Bedaquiline price reduction could benefit patients worldwide

During a pre-conference event of the International AIDS Conference in Amsterdam this year, the Minister of Health of South Africa, Mr. Aaron Motsoaledi, signed a deal with the manufacturer of Bedaquiline, Janssen, to drop the price of the drug from $750 to $400 for a full course.

South Africa is one of thirty countries high burden of Tuberculosis.

New drugs and regimens

Bedaquiline is one of two new drugs that have been introduced in the last 50 years specifically for the treatment of drug-resistant tuberculosis. With the rise of antimicrobial resistance, the arrival of new anti-TB drugs represents a major advancement in the care for patients with DR-TB and newfound hope to eliminate TB worldwide.

The World Health Organization released updated guidelines in May 2016 to standardize shorter regimens for DR-TB patients, significantly reducing treatment duration from up to 2 years to as little as 9 months using the new drugs Bedaquiline and Delamanid.

KNCV supports accessibility to new drugs

KNCV Tuberculosis Foundation through the USAID-funded, KNCV led Challenge TB has supported all the countries where we work to develop a policy framework, train staff, and expand diagnostic capacity, in an effort to ensure access is available for all eligible patients.

Individualized regimens containing Bedaquiline are now available in all 22 Challenge TB supported countries, while Delamanid is currently available in 14. Twenty countries are using the shorter regimen and will begin soon in the final two.

We hope this announcement will be the first of many such deals to bring life-saving new drugs and treatment regimens to all the TB patients who need them.

 

Read these stories of hope and how the new drugs and regimen are changing lives in Kyrgyzstan:

The Lack of Access to New Drugs is a Death Sentence

Curing the Untreatable

Continued Success

Curing TB in Record Time

All Patients are Entitled to Effective Medicines Against Drug-resistant tuberculosis

Baby Steps and Big Victories: Fighting Drug-Resistant TB in Kyrgyzstan

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Address

KNCV Tuberculosefonds
Maanweg 174
2516 AB Den Haag
+31 70 416 7222

OPEN IN GOOGLE MAPS

Postal address

Postbus 146
2501 CC Den Haag

More information

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.